Lundbeck
3
42M
3
0.14
1
1
- Areas of investment
Summary
Lundbeck is the famous Corporate Investor, which was founded in 2000.
Among the most popular portfolio startups of the fund, we may highlight benevolent.ai, Proximagen, Naurex. Among the most popular fund investment industries, there are Medical Device, Biopharma. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups.
The top amount of exits for fund were in 2015. Opposing the other organizations, this Lundbeck works on 4 percentage points more the average amount of lead investments. The typical startup value when the investment from Lundbeck is more than 1 billion dollars. The fund is generally included in less than 2 deals every year. The real fund results show that this Corporate Investor is 13 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2011. The common things for fund are deals in the range of 10 - 50 millions dollars.
The typical case for the fund is to invest in rounds with 3 participants. Despite the Lundbeck, startups are often financed by PathoCapital, Latterell Venture Partners, Genesys Capital. The meaningful sponsors for the fund in investment in the same round are Woodford Investment Management, Upsher Smith Laboratories, Takeda Pharmaceutical. In the next rounds fund is usually obtained by Woodford Investment Management, Takeda Ventures, Savitr Capital.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 0.14
- Investments by industry
- Biotechnology (3)
- Biopharma (1)
- Therapeutics (1)
- Medical (1)
- Health Care (1) Show 5 more
- Investments by region
-
- United Kingdom (2)
- United States (1)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 490M
- Group Appearance index
- 0.67
- Avg. company exit year
- 7
- Avg. multiplicator
- 3.45
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Naurex | 06 May 2014 | Biotechnology, Therapeutics, Biopharma | Late Stage Venture | 25M | United States, Illinois |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.